Harald Isemann, chairman of the Vienna Biocenter (VBC) - one of the leading life science hubs in Europe - and Managing Director of the Institute of Molecular Pathology (IMP), a VBC member, provides insights into the main tasks of the VBC, the organization of the IMP and the challenges it is facing.
Could you explain what the Vienna Biocenter is and its main mission?
"The VBC – some might say - is a mini city, with more than 1700 employees and 1300 students of 65 nationalities."
Alexander Biach, chairman of the Main Association of Austrian Social Security Institutions, discusses handling the responsibility for Austria’s Europe-leading social security coverage, current inefficiencies that need to be ironed out,…
Joy Ladurner, co-director of the NKSE (National Coordination Center for Rare Diseases) in Austria, discusses the rationale behind Austria’s prioritization of rare diseases and its leading role in the field.…
Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative…
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved…
Like a family recipe that has been refined and perfected over countless generations, Austria has developed a reputation as the quintessential clinical trials destination; a perfect combination of world-class academia,…
Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing…
See our Cookie Privacy Policy Here